Owens & Minor’s outlook remains ‘bullish’
By HME News Staff
Updated 9:22 AM CDT, Thu May 8, 2025
RICHMOND, Va. – Owens & Minor posted total revenue of just over $2.6 billion for the first quarter 2025, roughly flat to the same quarter in 2024.
Of that, Patient Direct accounted for $674 million in the first quarter of 2025 vs $638 million for the same period last year. Adjusted EBITDA for Patient Direct was nearly $98 million.
“Across the business we continued to see strong execution and progress toward our near and long-term strategies,” said Edward A. Pesicka, president & CEO. “Patient Direct delivered mid-single digit, top-line growth with strong performance in nearly all therapy categories, led by diabetes and sleep supplies. The top-line growth, combined with strong operational execution, delivered mid-teen expansion in EBITDA for the segment.”
Owens & Minor remains “actively engaged” in the sale process of its Products & Healthcare Services segment, Pesicka said.
In February, Owens & Minor also announced it was raising additional debt “while capital markets are attractive” to finance its acquisition of Rotech Healthcare, which it expects to close on in the first half of this year.
“Looking ahead, our focus remains on disciplined capital deployment, working toward our leverage target, successfully navigating potential changes in government policy, including tariffs, and integrating our planned acquisition of Rotech,” said Pesicka. “We remain bullish on the outlook for our Patient Direct segment and the strengthening of our P&HS businesses.”
Comments